HK1095154A1 - Hypo- and hyper-acetylated meningococcal capsular saccharides - Google Patents
Hypo- and hyper-acetylated meningococcal capsular saccharidesInfo
- Publication number
- HK1095154A1 HK1095154A1 HK07100474.8A HK07100474A HK1095154A1 HK 1095154 A1 HK1095154 A1 HK 1095154A1 HK 07100474 A HK07100474 A HK 07100474A HK 1095154 A1 HK1095154 A1 HK 1095154A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- capsular saccharides
- hypo
- hyper
- meningococcal capsular
- saccharides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0323103.2A GB0323103D0 (en) | 2003-10-02 | 2003-10-02 | De-acetylated saccharides |
PCT/IB2004/003366 WO2005033148A1 (fr) | 2003-10-02 | 2004-10-04 | Saccharides capsulaires meningococciques hypo et hyperacetyles |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1095154A1 true HK1095154A1 (en) | 2007-04-27 |
Family
ID=29415385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07100474.8A HK1095154A1 (en) | 2003-10-02 | 2007-01-12 | Hypo- and hyper-acetylated meningococcal capsular saccharides |
Country Status (17)
Country | Link |
---|---|
US (2) | US20100092509A1 (fr) |
EP (2) | EP2267036A1 (fr) |
JP (2) | JP5590760B2 (fr) |
CN (3) | CN102633893A (fr) |
AT (1) | ATE545659T1 (fr) |
AU (2) | AU2004278170B2 (fr) |
BR (1) | BRPI0415048A (fr) |
CA (1) | CA2541020C (fr) |
CY (3) | CY1112763T1 (fr) |
ES (1) | ES2379792T3 (fr) |
GB (1) | GB0323103D0 (fr) |
HK (1) | HK1095154A1 (fr) |
MX (1) | MXPA06003729A (fr) |
NZ (1) | NZ546668A (fr) |
PT (1) | PT1678212E (fr) |
RU (1) | RU2362784C2 (fr) |
WO (1) | WO2005033148A1 (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ530640A (en) | 1999-04-30 | 2006-06-30 | Chiron S | Conserved neisserial antigens |
CA2929348A1 (fr) | 1999-05-19 | 2000-11-30 | Novartis Vaccines And Diagnostics S.R.L. | Compositions a base de combinaisons de neisseria |
ES2391153T3 (es) * | 2000-02-28 | 2012-11-22 | Novartis Vaccines And Diagnostics S.R.L. | Expresión heteróloga de proteínas de Neisseria |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
EP1961427A3 (fr) * | 2002-08-02 | 2009-11-04 | GlaxoSmithKline Biologicals S.A. | Vaccin antineisseria comprenant une combinaison d'antigenes |
DE60335477D1 (de) * | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
PL1961426T3 (pl) | 2003-10-02 | 2012-03-30 | Gsk Vaccines S R L | Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
EP1931380A2 (fr) | 2005-09-01 | 2008-06-18 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Vaccination multiple comprenant des meningocoques du serogroupe c |
EP3020411A1 (fr) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Vaccin |
ES2670231T3 (es) | 2006-03-22 | 2018-05-29 | Glaxosmithkline Biologicals S.A. | Regímenes para inmunización con conjugados meningocócicos |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
JP2009531387A (ja) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
WO2009000825A2 (fr) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccin |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
EP2200642B1 (fr) | 2007-10-19 | 2012-04-18 | Novartis AG | Formulations de vaccin méningococcique |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
EP2367568A2 (fr) | 2008-12-17 | 2011-09-28 | Novartis AG | Vaccins méningococciques comprenant un récepteur de l'hémoglobine |
CA2756522C (fr) | 2009-03-24 | 2018-06-26 | Novartis Ag | Proteine de liaison du facteur h meningococcique utilisee comme adjuvant |
WO2010109324A1 (fr) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinaisons de protéine liant le facteur h de méningocoque et de conjugués de saccharide de pneumocoque |
NZ597191A (en) | 2009-06-22 | 2013-11-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
BRPI1015567A2 (pt) | 2009-06-22 | 2021-08-31 | Wyeth Llc | Composições imunogênicas de antígenos de staphylococcus aureus |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
BR112012009014B8 (pt) | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
RS56000B1 (sr) | 2009-10-30 | 2017-09-29 | Glaxosmithkline Biologicals Sa | Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida |
CA2793510A1 (fr) | 2010-03-18 | 2012-02-16 | Novartis Ag | Vaccins adjuvantes contre le meningocoque de serogroupe b |
AU2011268507B2 (en) | 2010-06-25 | 2014-08-14 | Novartis Ag | Combinations of meningococcal factor H binding proteins |
EP3246044B2 (fr) | 2010-08-23 | 2024-04-10 | Wyeth LLC | Formulations stables des antigènes rlp2086 de neisseria meningitidis |
ES2864635T3 (es) | 2010-09-10 | 2021-10-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
AU2011346535B2 (en) | 2010-12-22 | 2015-09-24 | Wyeth Llc | Stable immunogenic compositions of Staphylococcus aureus antigens |
JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および/またはアジュバントを有する混合ワクチン |
JP6088507B2 (ja) | 2011-07-08 | 2017-03-01 | ノバルティス アーゲー | チロシンライゲーションの方法 |
WO2013068949A1 (fr) | 2011-11-07 | 2013-05-16 | Novartis Ag | Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021 |
EP2797624A1 (fr) | 2011-12-29 | 2014-11-05 | Novartis AG | Combinaisons avec adjuvant de protéines méningococciques liant le facteur h |
US20150125486A1 (en) | 2012-03-08 | 2015-05-07 | Novartis Ag | Adjuvanted formulations of pediatric antigens |
MY167723A (en) | 2012-03-09 | 2018-09-21 | Pfizer | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
MX363511B (es) | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
ES2848048T3 (es) | 2012-10-03 | 2021-08-05 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas |
BR112015014250A2 (pt) | 2012-12-18 | 2017-07-11 | Glaxosmithkline Biologicals Sa | método para imunizar um bebê, vacina de combinação e, kit |
ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
US9359400B2 (en) | 2013-07-11 | 2016-06-07 | Novartis Ag | Site-specific chemoenzymatic protein modifications |
WO2015033251A2 (fr) | 2013-09-08 | 2015-03-12 | Pfizer Inc. | Compositions utilisables contre neisseria meningitidis et procédés associés |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
IL296681B2 (en) | 2014-01-21 | 2024-09-01 | Pfizer | Immunogenic preparations including conjugated capsular saccharide antigens and their uses |
HUE055553T2 (hu) | 2014-01-21 | 2021-12-28 | Pfizer | Streptococcus pneumoniae kapszulás poliszacharidok és azok konjugátumai |
EP3957321A3 (fr) | 2014-01-21 | 2022-07-13 | Pfizer Inc. | Polysaccharides capsulaires de streptococcus pneumoniae et conjugués de ceux-ci |
CA2939416A1 (fr) | 2014-02-14 | 2015-08-20 | Pfizer Inc. | Conjugues de glycoproteine immunogenes |
EP3229833A1 (fr) | 2014-12-10 | 2017-10-18 | GlaxoSmithKline Biologicals SA | Procédé de traitement |
CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
KR20190049940A (ko) | 2015-02-19 | 2019-05-09 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
PE20180172A1 (es) | 2015-05-04 | 2018-01-22 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
PE20240927A1 (es) | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
WO2017085586A1 (fr) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques |
US11389520B2 (en) * | 2016-01-28 | 2022-07-19 | Intravacc B.V. | Modified tetra-acylated neisserial LPS |
BR112018015237A2 (pt) * | 2016-01-28 | 2018-12-26 | De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport | lps de neisseria hexa-acilado modificado |
US20180064801A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
CA3033364A1 (fr) | 2016-09-02 | 2018-03-08 | Sanofi Pasteur, Inc. | Vaccin contre neisseria meningitidis |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
PL3570879T3 (pl) | 2017-01-20 | 2022-06-20 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
JP2018193446A (ja) * | 2017-05-15 | 2018-12-06 | 国立大学法人 長崎大学 | 新規多糖類 |
CA3120922A1 (fr) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations |
CA3136278A1 (fr) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations |
EP4203995A1 (fr) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Conjugués polysaccharide-protéine de streptococcus du groupe b, procédés de production de conjugués, compositions immunogènes comprenant les conjugués et leurs utilisations |
US20240000912A1 (en) | 2020-11-04 | 2024-01-04 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
EP4333879A1 (fr) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Vaccination contre des infections bactériennes et à betacoronavirus |
WO2022234416A1 (fr) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination contre des infections à pneumocoque et à covid-19 |
WO2024084397A1 (fr) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination contre infections à pneumocoques et à covid-19 |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
AU4841693A (en) | 1992-08-31 | 1994-03-29 | North American Vaccine, Inc. | Vaccines against group c neisseria meningitidis |
NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
ATE204762T1 (de) | 1993-03-23 | 2001-09-15 | Smithkline Beecham Biolog | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
NZ274376A (en) | 1993-09-22 | 1997-11-24 | Jackson H M Found Military Med | Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
EP0814833B1 (fr) | 1995-03-22 | 2003-05-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
TR199701547T1 (xx) | 1995-06-07 | 1998-03-21 | Smithkline Beecham Biologicals S.A. | Polisakarit antijen protein e�leni�i i�eren a��. |
DK0833662T4 (da) | 1995-06-23 | 2011-02-28 | Smithkline Beecham Biolog | Vaccinepræparat omfattende et Haemophilus influenza B-polysaccharidkonjugatantigen adsorberet på aluminiumphosphat |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
US6558677B2 (en) | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
PT1005368E (pt) | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
CA2308606A1 (fr) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Antigenes de neisseria |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
DE69941567D1 (de) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
CN101293920B (zh) | 1998-05-01 | 2012-07-18 | 诺华疫苗和诊断公司 | 脑膜炎奈瑟球菌抗原和组合物 |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
NZ509986A (en) | 1998-08-19 | 2003-10-31 | Baxter Healthcare S | Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines |
EP1144998A3 (fr) | 1998-10-09 | 2002-08-07 | Chiron Corporation | Sequences genomiques de neisseria et procedes d'utilisation |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
EP1034792A1 (fr) | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Administration par voie intranasale de vaccins à base de polyosides de Pneumococcus |
WO2000056360A2 (fr) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccin |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
WO2000061761A2 (fr) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Support proteique recombinant de la toxine a pour vaccins conjugues polysaccharides |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
CN1391483A (zh) | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
AR025749A1 (es) | 1999-09-24 | 2002-12-11 | Smithkline Beecham Biolog | Vacunas |
GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
RU2279889C2 (ru) | 2000-01-17 | 2006-07-20 | Чирон С.Р.Л. | ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В |
EP1311288A1 (fr) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Acides nucleiques immunostimulateurs permettant d'induire une reponse immunitaire th2 |
ES2391153T3 (es) | 2000-02-28 | 2012-11-22 | Novartis Vaccines And Diagnostics S.R.L. | Expresión heteróloga de proteínas de Neisseria |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
EP1946769B1 (fr) | 2000-06-29 | 2012-05-30 | SmithKline Beecham Biologicals S.A. | Composition de vaccin multivalente avec dose réduite de Haemophilus influenzae type B |
EP1322328B1 (fr) | 2000-07-27 | 2014-08-20 | Children's Hospital & Research Center at Oakland | Vaccins pour protection a large spectre contre les maladies causees par neisseria meningitidis |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
KR100865706B1 (ko) | 2000-09-26 | 2008-10-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
PL226184B1 (pl) | 2001-01-23 | 2017-06-30 | Aventis Pasteur | Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko |
GB0103169D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
WO2003009869A1 (fr) | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccins comprenant des adjuvants aluminium et histidine |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
WO2003035836A2 (fr) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5' |
GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
EP1777236B8 (fr) | 2002-03-26 | 2017-02-22 | GlaxoSmithKline Biologicals SA | Saccharide modifié présentant une stabilité améliorée dans l'eau destiné à être utilisé comme médicament |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
EP2172213B1 (fr) | 2003-01-30 | 2013-04-03 | Novartis AG | Vaccins injectables contre les multiples serogroupes du meningocoque |
EP1603950A2 (fr) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene |
BRPI0411815A (pt) | 2003-06-23 | 2006-08-08 | Baxter Int | vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas |
-
2003
- 2003-10-02 GB GBGB0323103.2A patent/GB0323103D0/en not_active Ceased
-
2004
- 2004-10-04 ES ES04791697T patent/ES2379792T3/es active Active
- 2004-10-04 JP JP2006530760A patent/JP5590760B2/ja active Active
- 2004-10-04 CN CN201110359118XA patent/CN102633893A/zh active Pending
- 2004-10-04 RU RU2006114695/04A patent/RU2362784C2/ru not_active IP Right Cessation
- 2004-10-04 PT PT04791697T patent/PT1678212E/pt unknown
- 2004-10-04 AU AU2004278170A patent/AU2004278170B2/en not_active Ceased
- 2004-10-04 EP EP10180746A patent/EP2267036A1/fr not_active Ceased
- 2004-10-04 CN CNA2004800345251A patent/CN1882612A/zh active Pending
- 2004-10-04 CA CA2541020A patent/CA2541020C/fr active Active
- 2004-10-04 US US10/574,437 patent/US20100092509A1/en not_active Abandoned
- 2004-10-04 AT AT04791697T patent/ATE545659T1/de active
- 2004-10-04 WO PCT/IB2004/003366 patent/WO2005033148A1/fr active Application Filing
- 2004-10-04 MX MXPA06003729A patent/MXPA06003729A/es active IP Right Grant
- 2004-10-04 CN CN2012104254031A patent/CN102977219A/zh active Pending
- 2004-10-04 BR BRPI0415048-1A patent/BRPI0415048A/pt not_active IP Right Cessation
- 2004-10-04 NZ NZ546668A patent/NZ546668A/en not_active IP Right Cessation
- 2004-10-04 EP EP04791697A patent/EP1678212B1/fr not_active Revoked
-
2007
- 2007-01-12 HK HK07100474.8A patent/HK1095154A1/xx not_active IP Right Cessation
-
2008
- 2008-06-19 AU AU2008202708A patent/AU2008202708B2/en not_active Ceased
-
2012
- 2012-02-13 JP JP2012028524A patent/JP2012097284A/ja not_active Withdrawn
- 2012-05-08 CY CY20121100422T patent/CY1112763T1/el unknown
- 2012-08-14 CY CY2012025C patent/CY2012025I1/el unknown
- 2012-08-14 CY CY2012024C patent/CY2012024I1/el unknown
-
2014
- 2014-05-01 US US14/267,248 patent/US9827301B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CY1112763T1 (el) | 2015-08-05 |
CA2541020A1 (fr) | 2005-04-14 |
US9827301B2 (en) | 2017-11-28 |
EP1678212B1 (fr) | 2012-02-15 |
RU2362784C2 (ru) | 2009-07-27 |
BRPI0415048A (pt) | 2006-12-12 |
CY2012025I1 (el) | 2015-08-05 |
PT1678212E (pt) | 2012-04-03 |
RU2006114695A (ru) | 2007-11-10 |
CY2012024I1 (el) | 2015-08-05 |
EP1678212A1 (fr) | 2006-07-12 |
JP2012097284A (ja) | 2012-05-24 |
AU2004278170B2 (en) | 2008-07-03 |
CA2541020C (fr) | 2015-12-01 |
CN102633893A (zh) | 2012-08-15 |
AU2004278170A1 (en) | 2005-04-14 |
GB0323103D0 (en) | 2003-11-05 |
MXPA06003729A (es) | 2006-06-23 |
ATE545659T1 (de) | 2012-03-15 |
JP2007507578A (ja) | 2007-03-29 |
ES2379792T3 (es) | 2012-05-03 |
JP5590760B2 (ja) | 2014-09-17 |
AU2008202708A1 (en) | 2008-07-10 |
US20100092509A1 (en) | 2010-04-15 |
WO2005033148A1 (fr) | 2005-04-14 |
CN102977219A (zh) | 2013-03-20 |
EP2267036A1 (fr) | 2010-12-29 |
US20140234368A1 (en) | 2014-08-21 |
CN1882612A (zh) | 2006-12-20 |
NZ546668A (en) | 2009-06-26 |
AU2008202708B2 (en) | 2010-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1095154A1 (en) | Hypo- and hyper-acetylated meningococcal capsular saccharides | |
PT1235589E (pt) | Composições compreendendo antigénios da neisseria meningitidis dos serogrupos b e c, e outro antigénio | |
ATE552844T1 (de) | Injizierbarer impfstoff gegen multiple meningokokken-serogruppen | |
GB0409745D0 (en) | Compositions including unconjugated carrier proteins | |
WO2003094834A3 (fr) | Vaccins muqueux avec adjuvant de chitosane et/ou antigenes meningococciques | |
UA92579C2 (ru) | Поливалентная менингококовая полисахаридно-белковая конъюгированная вакцина | |
WO2002091998A3 (fr) | Nouveau vaccin conjugue contre la meningite | |
MA30065B1 (fr) | Vaccin | |
EA200801368A1 (ru) | Конъюгатные вакцины | |
EP2277537A3 (fr) | Vaccin conjugué combiné contre Neisseria meningitidis | |
CY1110140T1 (el) | Εμβολιασμος με μηνιγγοκοκκικο συζευγμα | |
NO20076302L (no) | Immunogen sammensetning | |
PT1154790E (pt) | Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg | |
GB0406013D0 (en) | Analysis of saccharide vaccines without interference | |
WO2004103400A3 (fr) | Conjugues de polysaccharides-proteines derivatises meningococciques multivalents et vaccin correspondant | |
UA95075C2 (uk) | Імуногенна композиція |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHRG | Changes in the register |
Free format text: ADDITION OF INVENTOR: BERTI, FRANCESCO |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20171004 |